BioPharmaDispatch is continually collating information on the major procurement and manufacturing deals and clinical development updates and national administration programs.
WHAT IS NEW TODAY?
According to Bloomberg, the number of COVID-19 vaccines administered globally is 4.1 billion across 176 countries. The latest daily rate of doses administered is 40.2 million. COVAX has so far shipped over 153.6 million COVID-19 vaccines to 137 participants.
Israel has become the first country in the world to start administering a third 'booster' dose to seniors. The country launched its national immunisation program in December last year and it quickly administered doses to a majority of its population. However, it has recently experienced an increase in the number of cases with some experts arguing the vaccines have declining efficacy after six to 12 months.
Previous information on issues like country advance purchase agreements and vaccine development is available here.
COVID-19 VACCINE PROGRAMS - WHO IS VACCINATING AND HOW MANY?
The table below, which is based on data collected from Our World in Data, the US Centers for Disease Control and Prevention, Israel's Ministry of Health and the UK Department of Health and Social Care, includes a country-by-country breakdown of the number of people and the proportion of the population to have received at least one dose of COVID-19 vaccine or been fully vaccinated.
| Country | Pop. at least one dose | Pop. two doses | Doses administered |
| Singapore |
73.3 per cent | 55.8 per cent | 7.4 million |
| Denmark |
72.2 per cent | 54.2 per cent | 7.2 million |
| Canada |
71.4 per cent | 58.6 per cent | 49 million |
| Netherlands |
69.2 per cent | 50.5 per cent | 19.7 million |
| Belgium |
69 per cent | 57.2 per cent | 14.3 million |
| United Kingdom |
68.9 per cent | 55.9 per cent | 84.7 million |
| Portugal |
68.4 per cent | 55.2 per cent | 12 million |
| Spain |
65.9 per cent | 57.6 per cent | 56.1 million |
| Israel | 66.8 per cent | 62 per cent | 11.1 million |
| Ireland |
66.7 per cent | 55.6 per cent | 5.8 million |
| Finland |
66.5 per cent | 34.8 per cent | 5.6 million |
| Norway |
65.8 per cent | 33.2 per cent | 5.3 million |
| Italy |
63.4 per cent | 51.6 per cent | 68.1 million |
| Sweden |
63.3 per cent | 41.3 per cent | 10.5 million |
| France |
61.7 per cent | 47.1 per cent | 72.6 million |
| Germany |
61.2 per cent | 51.6 per cent | 92 million |
| Austria |
58.7 per cent | 50.7 per cent | 9.6 million |
| Hungary |
58.1 per cent | 56.2 per cent | 10.1 million |
| United States |
57 per cent | 49.1 per cent | 344.9 million |
| Argentina |
54.8 per cent | 14.9 per cent | 31.4 million |
| Greece |
54.6 per cent | 49.1 per cent | 10.4 million |
| Switzerland |
53.2 per cent | 47.6 per cent | 8.9 million |
| Czechia |
52.6 per cent | 45 per cent | 10.3 million |
| Lithuania |
51.8 per cent | 45.5 per cent | 2.6 million |
| Brazil |
48.7 per cent | 19.1 per cent | 140.1 million |
| Poland |
48.3 per cent | 46 per cent | 34.3 million |
| Estonia |
48 per cent | 37.2 per cent | 1.1 million |
| Slovenia |
44.2 per cent | 38.9 per cent | 1.7 million |
| Malaysia |
41.7 per cent | 20.1 per cent | 20 million |
| Serbia |
41.6 per cent | 39.6 per cent | 5.5 million |
| Slovakia |
41.4 per cent | 35.9 per cent | 4.2 million |
| Latvia |
40.6 per cent | 36.1 per cent | 1.3 million |
| Croatia |
40 per cent | 34.7 per cent | 3 million |
| Japan |
38.6 per cent | 27.8 per cent | 84 million |
| South Korea | 36.5 per cent | 13.8 per cent | 24.6 million |
| Mexico |
35.6 per cent | 19.8 per cent | 65.6 million |
| Australia | 32.5 per cent | 14.6 per cent | 12.2 million |
| India |
26.1 per cent | 7.4 per cent | 461.5 million |
| New Zealand | 22 per cent | 14.5 per cent | 1.7 million |
| Indonesia |
17.1 per cent | 7.4 per cent | 66.9 million |
| Bulgaria |
14.8 per cent | 14.4 per cent | 2 million |
THE CHRONOLOGY OF COVID-19 VACCINE DEVELOPMENT, DEALS AND PROGRAMS
There have been over 50 announced COVID-19 vaccine advance purchase and manufacturing agreements.
| January 2020 | |
| 23 | CEPI backs Inovio, The University of Queensland and Moderna |
| 31 | CEPI backs CureVac |
| March 2020 | |
| 10 | CEPI backs Novavax and The University of Oxford (AstraZeneca-Oxford) |
| 11 | Australia commits $3 million to The University of Queensland |
| 18 | CEPI backs the University of Hong Kong |
| 19 | CEPI backs Institut Pasteur-Themis |
| 30 | US commits US$456 million to J&J for development and manufacturing (100 million doses) |
| April 2020 | |
| 16 | US commits US$483 million to Moderna for development and manufacturing |
| 27 | CEPI backs Clover Biopharmaceuticals |
| 29 | Catalent announces deal to manufacture J&J |
| May 2020 | |
| 11 | CEPI extends relationship with Novavax with an additional US$384 million |
| 17 | UK commits US$110 million to AstraZeneca-Oxford for 100 million doses |
| 31 | US commits US$1.2 billion for 400 million doses of AstraZeneca-Oxford |
| June 2020 | |
| 2 | Australia commits an additional $2 million to The University of Queensland |
| 4 | CEPI commits US$383 million for 300 million doses of AstraZeneca-Oxford |
| Serum Institute of India agrees to manufacture 1 billion doses of AstraZeneca-Oxford | |
| US Department of Defence commits US$60 million to Novavax for 10 million doses | |
| 5 | CEPI extends relationship with The University of Queensland in collaboration that includes CSL |
| 13 | Europe’s IVA commits US$885 million for 400 million doses of AstraZeneca-Oxford |
| 15 | Catalent announces deal to ‘fill and finish’ AstraZeneca-Oxford |
| 25 | Catalent announces deal to ‘fill and finish’ Moderna |
| 29 | Brazil commits US$127 million for 30 million doses of AstraZeneca-Oxford |
| July 2020 | |
| 7 | CEPI extends deal with Clover Biopharmaceuticals with US$66 million |
| US commits US$1.6 billion to Novavax in return for 100 million doses. | |
| 20 | UK secures 40 million doses of Pfizer-BioNTech (financial terms undisclosed) |
| 21 | South Korea announces local company SK Bioscience will manufacture AstraZeneca-Oxford |
| 22 | US commits US$1.95 billion to Pfizer-BioNTech for 600 million doses |
| 26 | US commits an additional US$472 million to Moderna |
| 29 | UK commits US$650 million to Sanofi-GSK for 60 million doses |
| 31 | Japan deal with Pfizer-BioNTech for 120 million doses |
| US commits US$2.1 billion to Sanofi-GSK for 100 million doses | |
| EU secures 300 million doses of Sanofi-GSK. | |
| August 2020 | |
| 3 | UK partners with Wockhardt to expand capacity to manufacture AstraZeneca-Oxford |
| 6 | Chinese firm BioKangtai to manufacture AstraZeneca-Oxford |
| Serum Institute of India to manufacture one billion doses of Novavax | |
| 7 | Takeda agrees to manufacture Novavax in Japan |
| 7 | Switzerland secures 4.5 million doses of Moderna |
| 11 | Brazil commits an additional US$356 million for 100 million doses of AstraZeneca-Oxford |
| 12 | US commits another US$1.5 billion to Moderna for its first 100 million doses |
| 13 | South Korea announces local company SK Bioscience will manufacture antigen for Novavax |
| Indonesian company PT Bio Farma to manufacture Sinovac | |
| EU secures 200 million doses of J&J while Indian company Biological E will produce the vaccine | |
| 14 | EU secures 400 million doses of AstraZeneca-Oxford |
| Argentina and Mexico to produce 250 million doses of AstraZeneca-Oxford | |
| 16 | UK commits to Novavax for 60 million doses to be produced at the FUJIFILM site in the UK |
| 17 | UK commits to J&J for 30 million doses with the option of an additional 22 million |
| 18 | Australia announces ‘letter of intent’ to negotiate an agreement for AstraZeneca-Oxford |
| 20 | EU commits to CureVac for 225 million doses and an option of an additional 180 million |
| 21 | Sweden commits to EU's deal for AstraZeneca-Oxford |
| 24 | Catalent expands deal to manufacture AstraZeneca-Oxford drug substance |
| 26 |
Estonia secures 1.3 million doses of AstraZeneca-Oxford |
| Kazakhstan secures up to 7 million doses of Gamaleya Institute | |
| 27 | EU commits US$400 million downpayment to AstraZeneca-Oxford |
| 28 | Chinese company Sinovac commits to supply 40 million doses to Indonesia from November |
| 31 | Canada - 76 million doses of Novavax, 38 million J&J, 56 million Moderna and 20 million Pfizer |
| 31 | Canada to create a manufacturing facility in Montréal to produce 2 million doses per month |
| September 2020 | |
| 1 | OxfordBiomedica deal to set aside manufacturing capacity for AstraZeneca-Oxford |
| 2 | Catalent invests US$50m for new lines in the US to 'fill and finish' COVID-19 vaccines |
| 7 | Australia announces deals with AstraZeneca and CSL for around 54 million doses |
| 9 | Pfizer and BioNTech close to finalising 200 million dose deal with the European Union. |
| Russia to supply 32 million doses of 'Sputnik V' to Mexico | |
| 14 | UK secures 60 million doses of Valneva vaccine |
| 15 |
Germany invests US$445 million in the development of Pfizer-BioNTech |
| Novavax extends deal with Serum Institute of India to manufacture additional one billion doses | |
| 18 | BioNTech acquires manufacturing facility from Novartis to produce 750 million doses per year |
| 19 | EU finalised a deal for 300 million doses of Sanofi-GSK |
| 22 | Canada secures 72 million doses of Sanofi-GSK |
| 25 | Grand River Aseptic Manufacturing to 'fill and finish' 100 million doses of J&J for US market |
| 26 | Canada deal for 20 million doses of AstraZeneca-Oxford |
| 28 | CEPI doubles vaccine deal with Serum Institute of India to 200 million doses |
| October 2020 | |
| 8 | Australia announces 'final supply' commitment for 51 million doses of CSL-UQ |
| 9 | EU finalises deal for up to 400 million doses of J&J |
| 10 | New Zealand secures 1.5 million doses of Pfizer |
| 13 | Siam Bioscience to manufacture AZ-Oxford for distribution in Thailand and other Asian nations. |
| 14 | Indonesia secures 100 million doses of AZ-Oxford |
| 16 | Switzerland secures 5.3 million doses of AZ-Oxford |
| 18 | Mexico secures 90 million doses of three vaccines - Pfizer, AZ-Oxford and CanSino Biologics |
| 28 | GSK and Sanofi to supply 200 million doses to COVAX facility |
| 29 | Japan secures 50 million doses of Moderna |
| 30 | US Army secures 200 million doses of AstraZeneca-Oxford |
| November 2020 |
|
| 2 | Aspen contracted to manufacture J&J in South Africa |
| 3 | CEPI commits another US$260 million to Clover |
| 5 | Australia secures 10 million doses of Pfizer and 40 million doses of Novavax |
| 9 | Pfizer-BioNTech report 90 per cent efficacy in a late-stage trial |
| 11 | EU finalised deal for up to 300 million doses of Pfizer-BioNTech |
| 16 | Moderna reports 94.5 per cent efficacy in late-stage trial |
| 18 |
Pfizer-BioNTech update efficacy to 95 per cent |
| New Zealand secures up to five million doses of J&J | |
| 24 | EU finalised deal for 160 million doses of Moderna |
| December 2020 | |
| 2 | UK authorises use of Pfizer-BioNTech |
| 5 | Russia launches national COVID-19 immunisation program |
| 7 | Bahrain approves Pfizer-BioNTech |
| 8 | UK launches national COVID-19 immunisation program |
| 9 | Canada authorises use of Pfizer-BioNTech |
| 11 |
CSL and UQ scrap development of vaccine candidate |
| Australian government procures additional 20 million AZ-Oxford and 11 million Novavax | |
| US FDA vaccine advisory committee votes 17-4 to recommend Pfizer-BioNTech | |
| FDA authorises use of Pfizer-BioNTech | |
| 12 |
US procures additional 100 million Moderna and 100 million of Pfizer-BioNTech |
| Mexico authorises Pfizer-BioNTech | |
| 14 | US launches national COVID-19 immunisation program |
| 16 | China secures 100 million Pfizer-BioNTech |
| 17 | New Zealand secures 7.6 million AstraZeneca-Oxford and 10.72 million Novavax |
| 18 | US authorises Moderna |
| 18 | Israel launches national COVID-19 immunisation program |
| 21 | European Medicines Agency recommends authorising Pfizer-BioNTech |
| 22 | Europe, Qatar and Oman authorise the use of Pfizer-BioNTech |
| 23 |
The United Arab Emirates adds Pfizer-BioNTech to national immunisation program (Sinopharm) |
| Spain set to launch national immunisation program with Pfizer-BioNTech | |
| South Korea secures 20 million doses of Pfizer-BioNTech and 6 million doses of J&J | |
| J&J secures 6.4 million doses of AZ-Oxford | |
| US secures another 100 million doses of Pfizer-BioNTech | |
| 24 | Ireland authorises Pfizer-BioNTech |
| 26 | Europe launches immunisation program across all member states |
| 29 |
Europe secures another 100 million doses of Pfizer-BioNTech |
| UK authorises AZ-Oxford | |
| 30 | Indonesia secures 50 million doses of AstraZeneca-Oxford and 50 million doses of Novavax |
| 31 | WHO authorises PfizerBioNTech |
| January 2021 | |
| 3 | India authorises AZ-Oxford and Bharat Biotech’s Covaxin |
| 4 | Vietnam secures 30 million doses of AZ-Oxford |
| 5 | Mexico authorises AZ-Oxford and Israel authorises Moderna |
| 6 | Europe authorises Moderna and secures another 300 million doses of Pfizer-BioNTech |
| 9 | UK authorises Moderna |
| 11 | Malaysia secures another 12.2 million doses of Pfizer-BioNTech (adding to 12.8 million doses) |
| 15 | India launches national immunisation program |
| 17 | Brazil authorises AZ-Oxford and Sinovac but rejects Russia's 'Sputnik V' COVID-19 vaccine |
| 20 |
Japan secures another 24 million doses of Pfizer-BioNTech |
| African Union secures 270 million doses outside global COVAX facility | |
| 22 |
COVAX secures 40 million doses of Pfizer-BioNTech |
| COVAX secures 150 million doses of AstraZeneca-Oxford | |
| 25 | Australia authorises Pfizer-BioNTech |
| 26 | EU imposes controls and potential restrictions on export of vaccines manufactured in the union |
| 27 |
US secures 200 million doses of Pfizer-BioNTech and Moderna |
| Sanofi to produce 125 million doses of Pfizer-BioNTech | |
| 28 | The Pasteur Institute scraps development of its vaccine |
| 29 |
EU authorises AstraZeneca-Oxford while imposing export restrictions |
| Novavax 89.3 per cent effective in a late-stage UK trial | |
| J&J 72 per cent effective in the US | |
| 30 | Hungary approves Sinopharm vaccine following its agreement to buy Russia's 'Sputnik V' |
| February 2021 |
|
| 1 |
Clover Pharmaceuticals to initiate phase 2/3 trial of vaccine candidate |
| AstraZeneca will supply an additional 9 million doses to the EU in the first quarter of 2021 | |
| 2 | Bayer to manufacture doses of CureVac |
| 3 |
AstraZeneca-Oxford cut transmission by 67 per cent |
| Russia’s 'Sputnik V' vaccine almost 92 per cent effective | |
| 4 | GSK partners with CureVac on potential multi-variant vaccine |
| 6 | AZ-Oxford submits for authorisation in Japan |
| 8 | Pfizer-BioNTech finalise January deal for 300 million additional doses to EU |
| 10 |
WHO says AZ-Oxford is safe and effective |
| New Zealand approves Pfizer-BioNTech | |
| 12 | Japan approves Pfizer-BioNTech |
| 15 | WHO approves AZ-Oxford vaccines produced in India and South Korea |
| 16 |
Australia approves AZ-Oxford |
| South Korea secures additional 40 million doses of Novavax and 6 million Pfizer-BioNTech | |
| The number of daily doses administered globally topped 6 million for the first time | |
| 17 |
Japan launches national immunisation program |
| Europe secures another 150 million doses of Moderna | |
| 18 | COVAX secures 1.1 billion doses of Novavax |
| 19 | New Zealand launches national immunisation program |
| 21 | Australia launches national immunisation program |
| 22 |
Sanofi will produce 12 million doses of J&J per month at a facility in France |
| Sanofi-GSK to launch phase two trial of new COVID-19 vaccine | |
| 24 |
COVAX ships its first 600,000 doses to Ghana |
| FDA analysis confirms J&J safe and effective | |
| 25 | Data from real-world study confirms high efficacy of Pfizer-BioNTech |
| 27 | US FDA authorises J&J |
| 28 | AZ divests 7.7 per cent stake in Moderna |
| March 2021 | |
| 1 | UK data shows AZ-Oxford/Pfizer-BioNTech 80 per cent effective at preventing hospitalisation |
| 2 | COVAX delivers doses to Nigeria, Congo, Angola, Senegal and Gambia |
| 5 | COVAX confirms delivery of 12 million doses to 19 countries in first week of program |
| 8 |
Baxter to 'fill and finish' 60-90 million doses of Moderna |
| COVAX delivers 468,000 doses to Afghanistan | |
| 9 | Pfizer-BioNTech effective against 'Brazilian' COVID-19 strain |
| 10 | US to acquire another 100 million doses of J&J |
| 11 |
Lilly's antibodies (bamlanivimab and etesevimab) effective against COVID-19 |
| COVAX delivers 144,000 doses to Benin | |
| 11 | EU approves J&J with deliveries to start in April |
| 12 | The 'quad' partnership - Australia, US, Japan, India - to provide one billion doses to Indo-Pacific |
| 15 |
COVAX says it has now delivered 29 million vaccine doses to 46 countries |
| Several European countries cease rollout of AZ-Oxford after reports of blood clots | |
| 16 |
Moderna launches a trial to test its vaccine in children younger than 12. |
| Jamaica receives 14,400 doses from COVAX | |
| 18 | Europe's regulator says AZ-Oxford is safe and not linked to blood clots |
| 20 | COVAX delivers 24,000 doses of AZ-Oxford to the Solomon Islands |
| 22 | US study finds AZ-Oxford 79 per cent effective against COVID-19 |
| 23 | COVAX sends 85,000 doses to El Salvador and 228,000 to Bolivia |
| 26 | COVAX sends 336,000 doses to Iraq and 132,000 to South Sudan |
| 29 | African Union secures 400 million doses of J&J |
| 30 | COVAX sends 218,000 doses to Argentina and 24,000 to Botswana |
| April 2021 | |
| 1 | COVAX sends 811,000 doses to Vietnam and 33,600 to Belize. |
| 5 |
Indian contract manufacturer Panacea Biotech agreed to produce Russia's 'Sputnik V' vaccine |
| CSL and Takeda halt development of plasma-derived COVID-19 treatment that failed a trial | |
| 7 | UK people under 30 will not be offered AZ-Oxford due to rare risk of blood clots |
| 8 | COVAX sends 43,200 doses to Costa Rica and 62,800 to Barbados. |
| 9 | Australia limits use of AZ-Oxford to people aged over 50 |
| 10 | COVAX sends 58,000 doses to Libya and 4,800 to Tuvalu |
| 12 | UK expands national immunisation program to people aged over 40 |
| 13 | India approved use of the Russian 'Sputnik V' vaccine |
| 14 | US and UK pause rollout of J&J after reports of blood clots |
| COVAX sends 106,000 doses to Papua New Guinea and 228,000 to Zambia |
|
| Moderna over 90 per cent effective six months after the second dose | |
| 16 | COVAX sends 24,000 doses to Namibia and 117,000 to Ukraine |
| 17 | Japan secures additional doses of Pfizer-BioNTech |
| 19 | EU exercises option for additional 100 million doses of Pfizer-BioNTech |
| 20 | COVAX sends 24,000 doses to Fiji and 146,400 to Jordan |
| 23 | US will resume use of J&J after clearance from the FDA |
| 26 | Sanofi to 'fill and finish' Moderna at US facility |
| 27 |
COVAX sends 3.8 million doses to Indonesia and 134,400 to Paraguay |
| US authorises the export of US-made doses of Pfizer-BioNTech to Mexico |
|
| 28 | UK secures additional 60 million doses of Pfizer-BioNTech |
| May 2021 | |
| 1 | US authorises the export of US-made doses of Pfizer-BioNTech to Canada |
| 3 | COVAX secures 500 million doses of Moderna and WHO authorises the vaccine |
| 4 | COVAX sends a second 3.891 million doses to Brazil |
| 5 | Canada authorises Pfizer-BioNTech for people aged 12-15 |
| 6 | US and Australia back move to waive IP protection for COVID-19 vaccines |
| 7 | EU officially secures 1.8 billion doses of Pfizer-BioNTech |
| 8 | WHO authorises use of vaccine produced by China's Sinopharm |
| 10 | FDA authorised use of the Pfizer-BioNTech for 12-15-year-olds. |
| 12 | Australia secures 25 million doses of Moderna |
| 17 | Sanofi-GSK advance two-shot recombinant candidate to phase 3 trial |
| 19 | Indian company Biological E. to manufacture 600 million doses of J&J |
| 21 |
Germany to donate EURO100million and 30 million doses to COVAX |
| Japan authorises Moderna and AZ-Oxford | |
| COVAX secures 200 million doses of J&J | |
| 25 | Moderna 100 per cent effective in a late-stage involving adolescents aged 12 to 17. |
| 27 | Sanofi-GSK start enrollment in the Phase 3 study of their COVID-19 vaccine candidate |
| 28 | UK approves J&J single-shot vaccine |
| June 2021 |
|
| 1 | WHO authorises Sinovac |
| 2 | UK reports the first day of no COVID-19 deaths since the start of the pandemic |
| 4 | Canada secures option for 3 million doses of Pfizer-BioNTech |
| 12 | G7 agrees to supply one billion doses of vaccine to developing countries |
| 13 | Novavax 90.4 per cent effective against COVID-19 |
| 16 | US secures additional 200 million doses of Moderna |
| 17 |
Australia raises age threshold for AZ-Oxford to 60 |
| US to invest $US3 billion in development of COVID-19 treatments | |
| 22 | EU exercises option for additional 150 million doses of Moderna |
| 25 | Australia approves J&J (Janssen) |
| 28 | Early results from a UK study suggest mixing AZ-Oxford and Pfizer-BioNTech is effective |
| 30 |
COVAX secures 414 million doses of Clover Biopharmaceuticals |
| EU targeting five COVID-19 therapeutic interventions | |
| July |
|
| 5 | UK announces it will lift virtually all remaining pandemic restrictions from 19 July |
| 12 | COVAX secures 500 million doses of Sinovac and Sinopharm |
| 20 | EMA starts rolling review of Sanofi-GSK |
| 25 | Australia secures 85 million additional doses of Pfizer-BioNTech (2022 and 2023) |
| 31 | Israel becomes the first country to launch third 'booster' dose of vaccine |
